Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers

What Was Tested

This randomized controlled trial looks at Vasopressin and Desmopressin.

Desmopressin is usually administered intranasally in the treatment of central diabetes insipidus or nocturnal enuresis.

The sublingual administration of desmopressin is expected to be an alternative to the intranasal route with advantages to children and to patients with allergic rhinitis or chronic rhinosinusitis.

Therefore, the present study was carried out to explore the time-versus-concentration profile of desmopressin in plasma after sublingual administration to healthy volunteers.

Who Took Part

The abstract describes 16 volunteers taking part.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Safety and tolerability were assessed simultaneously.

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Diabetes Insipidus and Hemostatics.

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin in 16 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (International journal of clinical pharmacology and therapeutics), a journal based in Germany.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.